Skip to main content
. 2021 Mar 22;104(1):00368504211000906. doi: 10.1177/00368504211000906

Table 4.

Analysis of severe and non-severe patients of COVID-19 by using Mantel–Haenszel test.

Variable Number ofstudies OR 95% CI Severe Non-severe χ 2 I 2§ Z p
Male 40 1.46 1.34–1.60 1859 5120 43.78 11 8.29 <0.00001
Female 40 0.68 0.62–0.74 1159 4087 45.84 15 8.49 <0.00001
Clinical features
 Fever 34 1.24 0.96–1.60 1964 5955 102.36 68 1.67 0.09
 Cough 34 1.45 1.18–1.78 1660 4798 88.16 63 3.55 0.0004
 Fatigue 34 1.40 1.14–1.72 911 2287 91.54 64 3.21 0.001
 Sore throat 24 1.16 0.81–1.67 200 972 73.68 69 0.81 0.42
 Dyspnea 34 4.20 3.09–5.72 1534 8387 226.03 85 9.13 <0.00001
 Headache 28 0.95 0.69–1.31 232 736 66.56 59 0.31 0.76
 Diarrhea 33 1.25 0.98–1.61 434 979 69.95 54 1.80 0.07
 Nausea or vomiting 22 1.28 0.85–1.92 169 516 67.31 69 1.19 0.23
Co-morbidities
 Hypertension 35 1.98 1.62–2.42 1315 2333 107.88 68 6.62 <0.00001
 Diabetes 37 2.04 1.67–2.50 741 1316 80.57 55 6.97 <0.00001
 Cancer 28 1.75 1.40–2.18 142 221 36.70 26 4.92 <0.00001
 COPD 28 1.90 1.49–2.41 131 178 46.70 42 5.26 <0.00001
 Cardiovascular disease 31 2.78 2.00–3.86 452 694 120.06 75 6.10 <0.00001
 Chronic kidney disease 20 2.74 1.68–4.48 260 289 72.08 74 4.03 <0.00001
Complications
 ARDS 19 42.69 21.62–84.31 994 258 158.58 89 10.81 <0.00001
 Shock 11 23.95 9.50–60.35 180 21 23.84 58 6.74 <0.00001
 Acute kidney injury 17 11.12 6.07–20.38 560 263 102.42 84 7.80 <0.00001
 Arrhythmia 8 21.23 10.40–43.30 263 42 19.27 64 8.40 <0.00001
Treatments
 Antiviral 25 2.18 1.43–3.34 992 3345 86.40 76 3.60 0.0003
 Antibiotics 22 5.96 3.32–10.69 1296 3398 97.07 82 5.98 <0.00001
 Glucocorticoids 28 6.12 4.01–9.34 1347 1420 258.31 90 8.40 <0.00001
 Oxygen support 19 1.22 0.43–3.44 1104 2756 534.83 97 0.37 0.71
 CRRT 16 18.92 8.20–43.66 183 32 34.53 57 6.89 <0.00001
 NIV 15 41.27 15.24–111.77 599 87 119.85 88 7.32 <0.00001

OR: odds ratio; 95% CI: 95% confidence interval; ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; CRRT: continuous renal replacement therapy; NIV: noninvasive ventilation.

Chi-squared test for heterogeneity.

§

I2 index to quantify the degree of heterogeneity.

Z-statistics.